These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8415212)

  • 1. [Personal experience with combined treatment of gliclazide and insulin in patients with non-insulin-dependent diabetes (type 2) and late secondary failure of sulphonylureas].
    Zapecka-Dubno B; Wiśniewska K; Szczepanik Z; Kasperska-Czyzykowa T
    Pol Arch Med Wewn; 1993 Jun; 89(6):499-506. PubMed ID: 8415212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
    Chazan AC; Gomes MB
    Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)].
    Jedynasty K; Kasperska-Czyzykowa T; Stepień K; Nowaczyk R
    Pol Arch Med Wewn; 1998 Jun; 99(6):442-51. PubMed ID: 10085698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Beneficial effects of added glicazide in patients with type II diabetes mellitus treated with insulin].
    Ruas MM; Carvalheiro M; Geraldes E; Carrilho F; Bastos M; Fagulha A; Paiva I; Rodrigues F; Gomes L
    Acta Med Port; 1991; 4(2):76-8. PubMed ID: 1867120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
    Brogard JM; Pinget M; Dorner M
    Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Aschner P; Kattah W
    Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.
    Zurro Hernandez J; Lavielle R
    Curr Med Res Opin; 1986; 10(5):351-8. PubMed ID: 3816294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term improvement in insulin response with gliclazide treatment.
    Bodansky HJ; Medback S; Cudworth AG; Rees LH; de Silva RS
    Diabete Metab; 1982 Dec; 8(4):319-22. PubMed ID: 6761187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sulphonylurea administration on insulin secretion and amino acid metabolism in non-insulin-dependent diabetic patients.
    Paterson KR; Gyi KM; McBride D; Cohen HN; Shenkin A; Manderson WG; MacCuish AC
    Diabet Med; 1985 Jan; 2(1):38-40. PubMed ID: 2951064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up.
    Quatraro A; Consoli G; Ceriello A; Giugliano D
    Diabete Metab; 1986 Dec; 12(6):315-8. PubMed ID: 3545931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
    Noury J; Nandeuil A
    Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Golay A; Broquet C; Chabot V; Studer S; Felber JP
    Schweiz Med Wochenschr; 1984 Feb; 114(8):261-4. PubMed ID: 6369531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
    Ward G; Harrison LC; Proietto J; Aitken P; Nankervis A
    Diabetes; 1985 Mar; 34(3):241-5. PubMed ID: 3882491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.
    Ma A; Kamp M; Bird D; Howlett V; Cameron DP
    Aust N Z J Med; 1989 Feb; 19(1):44-9. PubMed ID: 2669710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gliclazide on non-insulin dependent diabetes mellitus.
    Wajchenberg BJ; Santomaruo AT; Cherem JJ; Malerbi DA; Giurno Filho A; Lerario AC; Giannella Neto D
    Adv Exp Med Biol; 1988; 246():313-9. PubMed ID: 3074661
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preliminary report on 30 cases of non-insulin-dependent diabetes (NIDD) treated with gliclazide].
    Pan CY
    Zhonghua Nei Ke Za Zhi; 1983 Jul; 22(7):426-8. PubMed ID: 6641388
    [No Abstract]   [Full Text] [Related]  

  • 19. Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics.
    Couturier E
    Diabetes Res Clin Pract; 1985-1986 Mar; 1(6):343-7. PubMed ID: 3915271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.